A multicenter, open-label, phase II study of tirabrutinib (ONO/GS-4059) in patients with Waldenstrom's macroglobulinemia (vol 111, pg 3327, 2020)

被引：0
|
作者：
Sekiguchi, Naohiro
Rai, Shinya
Munakata, Wataru
Suzuki, Kenshi
Handa, Hiroshi
Shibayama, Hirohiko
Endo, Tomoyuki
Terui, Yasuhito
Iwaki, Noriko
Fukuhara, Noriko
Tatetsu, Hiro
Iida, Shinsuke
Ishikawa, Takayuki
Shiibashi, Ryota
Izutsu, Koji
机构：
来源：
CANCER SCIENCE | 2021年 / 112卷 / 04期
关键词：
D O I：
10.1111/cas.14818
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1669 / 1669
页数：1
相关论文
共 50 条
  • [1] A multicenter, open-label, phase II study of tirabrutinib (ONO/GS-4059) in patients with Waldenstrom's macroglobulinemia
    Sekiguchi, Naohiro
    Rai, Shinya
    Munakata, Wataru
    Suzuki, Kenshi
    Handa, Hiroshi
    Shibayama, Hirohiko
    Endo, Tomoyuki
    Terui, Yasuhito
    Iwaki, Noriko
    Fukuhara, Noriko
    Tatetsu, Hiro
    Iida, Shinsuke
    Ishikawa, Takayuki
    Shiibashi, Ryota
    Izutsu, Koji
    CANCER SCIENCE, 2020, 111 (09) : 3327 - 3337
  • [2] Phase 2 Study of Tirabrutinib (ONO/GS-4059), a Second-Generation Bruton's Tyrosine Kinase Inhibitor, Monotherapy in Patients with Treatment-Naive or Relapsed/Refractory Waldenstrom Macroglobulinemia
    Munakata, Wataru
    Sekiguchi, Naohiro
    Shinya, Rai
    Suzuki, Kenshi
    Handa, Hiroshi
    Shibayama, Hirohiko
    Endo, Tomoyuki
    Terui, Yasuhito
    Iwaki, Noriko
    Fukuhara, Noriko
    Tatetsu, Hiro
    Iida, Shinsuke
    Ishikawa, Takayuki
    Shiibashi, Ryota
    Izutsu, Koji
    BLOOD, 2019, 134
  • [3] Phase I study of tirabrutinib (ONO-4059/GS-4059) in patients with relapsed or refractory B-cell malignancies in Japan
    Munakata, Wataru
    Ando, Kiyoshi
    Hatake, Kiyohiko
    Fukuhara, Noriko
    Kinoshita, Tomohiro
    Fukuhara, Suguru
    Shirasugi, Yukari
    Yokoyama, Masahiro
    Ichikawa, Satoshi
    Ohmachi, Ken
    Gion, Naokazu
    Aoi, Arata
    Tobinai, Kensei
    CANCER SCIENCE, 2019, 110 (05) : 1686 - 1694
  • [4] A Prospective, Open-Label, Multicenter, Phase 2 Trial to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib (ONO/GS-4059) and Entospletinib with and without Obinutuzumab in Patients with Relapsed/ Refractory Chronic Lymphocytic Leukemia (CLL)
    Kutsch, Nadine
    Pallasch, Christian
    Tausch, Eugen
    Boehme, Volkmar
    Ritgen, Matthias
    Liersch, Ruediger
    Wacker, Alexander
    Jacobs, Georg
    Trappe, Ralf Ulrich
    Dreger, Peter
    Stilgenbauer, Stephan
    Zhang, Danjie
    Jurgensmeier, Juliane M.
    Bhargava, Pankaj
    Hallek, Michael
    Eichhorst, Barbara F.
    BLOOD, 2019, 134
  • [5] Enzastaurin in Previously Treated Waldenstrom's Macroglobulinemia: An Open-Label, Multicenter, Phase II Study
    Ghobrial, Irene M.
    Harousseau, Jean-Luc
    Treon, Steven P.
    Harris, Brianna
    Lin, Courtney E.
    Yuan, Zheng
    Benhadji, Karim
    Wooldridge, James E.
    Leblond, Veronique
    BLOOD, 2009, 114 (22) : 1488 - 1488
  • [6] A Prospective, Open-Label, Multicenter, Phase 2 Trial to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib (ONO/GS-4059) and Idelalisib with and without Obinutuzumab in Patients with Relapsed/ Refractory Chronic Lymphocytic Leukemia (CLL)
    Kutsch, Nadine
    Pallasch, Christian
    Decker, Thomas
    Hebart, Holger
    Chow, Kai Uwe
    Graeven, Ullrich
    Kisro, Jens
    Kroeber, Alexander
    Tausch, Eugen
    Wendtner, Clemens-Martin
    Eckart, Michael J.
    Stilgenbauer, Stephan
    Huang, Xi
    Juergensmeier, Juliane M.
    Bhargava, Pankaj
    Hallek, Michael
    Eichhorst, Barbara F.
    BLOOD, 2019, 134
  • [7] A phase 2, open-label study of ibrutinib plus rituximab in Japanese patients with Waldenstrom's macroglobulinemia
    Izutsu, Koji
    Kato, Hisashi
    Sekiguchi, Naohiro
    Fujisaki, Tomoaki
    Kawakita, Toshiro
    Obara, Naoshi
    Matsue, Kosei
    Nishimoto, Mitsutaka
    Hatayama, Tomoyoshi
    Inagaki, Mitsuo
    Fujikawa, Ei
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2024, 120 (01) : 80 - 90
  • [8] Evaluation of orelabrutinib monotherapy in patients with relapsed or refractory Waldenstrom's macroglobulinemia in a single-arm, multicenter, open-label, phase 2 study
    Cao, Xin-Xin
    Jin, Jie
    Fu, Cheng-Cheng
    Yi, Shu-Hua
    Zhao, Wei-Li
    Sun, Zi-Min
    Yang, Wei
    Li, Deng-Ju
    Cui, Guo-Hui
    Hu, Jian-da
    Liu, Ting
    Song, Yong-Ping
    Xu, Bing
    Zhu, Zun-Min
    Xu, Wei
    Zhang, Ming-Zhi
    Tian, Ya-Min
    Zhang, Bin
    Zhao, Ren-Bin
    Zhou, Dao-Bin
    ECLINICALMEDICINE, 2022, 52
  • [9] Phase 1/2 Study of Tirabrutinib (ONO/GS-4059), a Next-Generation Bruton's Tyrosine Kinase (BTK) Inhibitor, Monotherapy in Patients with Relapsed/ Refractory Primary Central Nervous System Lymphoma (PCNSL)
    Nagane, Motoo
    Narita, Yoshitaka
    Mishima, Kazuhiko
    Terui, Yasuhito
    Arakawa, Yoshiki
    Yonezawa, Hajime
    Asai, Katsunori
    Fukuhara, Noriko
    Sugiyama, Kazuhiko
    Shinojima, Naoki
    Kitagawa, Junsaku
    Aoi, Arata
    Nishikawa, Ryo
    BLOOD, 2019, 134
  • [10] A multicenter, open-label, uncontrolled phase II study of ONO-4538 for cutaneous angiosarcoma (Angio Check study).
    Fujisawa, Yasuhiro
    Yoshino, Koji
    Isei, Taiki
    Namikawa, Kenjiro
    Fujimura, Taku
    Yasuda, Masahito
    Yamamoto, Yuki
    Uchi, Hiroshi
    Yanagi, Teruki
    Kato, Hiroshi
    Otsuka, Atsushi
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345